Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 14/20 | 0.40 |
| ▸ | THRA | P10827 | 13/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7250380 | 0.89 | NR3C1 (0.63) | NR3C1THRBTHRALMNA | |
| SCHEMBL7256648 | 0.87 | NR3C1 (0.65) | NR3C1THRBTHRA | |
| SCHEMBL7249537 | 0.81 | NR3C1 (0.70) | NR3C1THRBTHRA | |
| SCHEMBL7250359 | 0.81 | NR3C1 (0.70) | NR3C1THRBTHRA | |
| SCHEMBL7256644 | 0.80 | NR3C1 (0.69) | NR3C1THRBTHRA | |
| SCHEMBL7252350 | 0.80 | NR3C1 (0.69) | NR3C1THRBTHRA | |
| SCHEMBL7252391 | 0.80 | NR3C1 (0.69) | NR3C1THRBTHRA | |
| SCHEMBL7250384 | 0.79 | NR3C1 (0.67) | NR3C1THRBTHRA | |
| SCHEMBL7252616 | 0.79 | NR3C1 (0.67) | NR3C1THRBTHRA | |
| SCHEMBL7251527 | 0.78 | NR3C1 (0.66) | NR3C1THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | KARO BIO AB (SE) | 2003-09-04 | — | — | US | claimed |
| EP-1265839-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2002-12-18 | — | — | EP | claimed |
| WO-2001047859-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2001-07-05 | — | — | WO | claimed |
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | KARO BIO AB (SE) | 2003-09-04 | — | — | US | disclosed |
| EP-1265839-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001047859-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | NR3C1, NR3C2, GPR119 | NR3C1 1/4885THRB 167/4885THRA 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.